Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma-Reference-Cited by-同舟云学术

Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma

Published:2022-11-15 Issue:6 Volume:60 Page:1162-1170
ISSN:0277-0903
Container-title:Journal of Asthma
language:en
Short-container-title:Journal of Asthma

Author:

Menigoz C.¹^ORCID,Dirou S.¹^ORCID,Chambellan A.²^ORCID,Hassoun D.³^ORCID,Moui A.¹^ORCID,Magnan A.⁴^ORCID,Blanc F. X.¹^ORCID

Affiliation:

1. CHU Nantes, Service de Pneumologie, L’institut du thorax, Nantes Université, Nantes, France

2. CHU Nantes, Service d’Explorations Fonctionnelles, L’institut du thorax, Nantes Université, Nantes, France

3. CHU Nantes, CNRS, INSERM, L’institut du Thorax, Nantes Université, Nantes, France

4. Hôpital Foch, INRAe UMR 0892, Université de Versailles Saint-Quentin Paris-Saclay, Suresnes, France

Publisher

Informa UK Limited

Subject

Pulmonary and Respiratory Medicine,Immunology and Allergy,Pediatrics, Perinatology and Child Health

Link

https://www.tandfonline.com/doi/pdf/10.1080/02770903.2022.2136526

Reference44 articles.

1. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR)

2. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

3. Global Initiative for Asthma. Global strategy for asthma management and prevention. [accessed 2022 January 17). https://ginasthma.org/gina-reports/.

4. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population

5. IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endotyping Chronic Respiratory Diseases: T2 Inflammation in the United Airways Model;Life;2024-07-19

2. Comparaison de l’efficacité du dupilumab et des biothérapies ciblant la voie de l’interleukine 5 en vie réelle dans l’asthme sévère éosinophilique;Revue des Maladies Respiratoires Actualités;2024-01

3. Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient;Respiratory Medicine;2023-11

4. Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years’ Therapy;The Journal of Allergy and Clinical Immunology: In Practice;2023-09

5. Switching to Dupilumab from Other Biologics without a Treatment Interval in Patients with Severe Asthma: A Multi-Center Retrospective Study;Journal of Clinical Medicine;2023-08-09